Business
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
EMERYVILLE, Calif., Aug. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"EMERYVILLE, Calif., Aug. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that the company's executives will participate in the following investor events:\n\n \n \n \n \n \n \n\n \nInvestor Conference Details: \nMorgan Stanley Global Healthcare Conference in New York, NY on September 4, 2024Format: Fireside Chat with Mike Ulz at 11:30 am EDT and host investor meetingsWells Fargo Healthcare Conference in Boston, MA on September 5, 2024Format: Fireside Chat with Derek Archila at 2:15 pm EDT and host investor meetingsCantor Global Healthcare Conference in New York, NY on September 17, 2024Format: Fireside Chat with Eric Schmidt at 10:20 am EDT and host investor meetingsInvestors interested in scheduling a meeting with management during one of the investor conferences listed above should contact their Morgan Stanley, Wells Fargo, or Cantor sales representative.\nAbout Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. \nOur lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. \nKyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.\nForward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \"forward-looking statements.\" The words, without limitation, \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"...